FTC Gives Green Light To ANI-Novitium Acquisition Conditions
Follows Public Comment Period; ANI Announced Completion In November
ANI is now firmly in the clear for its $210m acquisition of Novitium, following FTC approval of an order requiring divestiture of rights and assets to two generic products. The US-based firm is on an upward trajectory following its recent approval for Cortrophin Gel.
You may also be interested in...
FTC’s Take On Two Pharma Mergers Shows Deals Can Clear Higher Hurdle
Pfizer’s acquisition of Arena without FTC intervention and Hikma’s acquisition of Custopharm with one product divestiture shows the commission is bound by anticompetitive facts of a deal. A more controversial merger may not get through, former FTC attorney says.
Deal Watch: How Did J.P. Morgan Deal-Making Compare To Prior Years?
Licensing deals and partnerships carried the day during another hectic J.P. Morgan Healthcare Conference. Pfizer racked up its third deal of the week in a cancer collaboration with Dren Bio.
ANI Snaps Up Novitium In Deal Worth Up To $210m
ANI Pharmaceuticals has struck a deal worth up to $210m to acquire niche generics specialist Novitium Pharma, a move that the firm says will bring it a healthy pipeline of ANDAs and 505(b)(2) products as well as enhancing its CDMO business.